FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/Wr3tG5izCi https://t.co/P8A5PUCIX0

#Cancers esp #hematologic & #lung are ⬆️in Pts w #inflammatory #rheum #diseases Odds ratios of hem malignancies are wide & risk stratification is imp Are we doing a good job? 🤔skin cancer screening ??- not as per general standards Abst#0172 #ACR25 @RheumNow @ACRheum https://t.co/Uve9knXD3o

Do you believe that patients w #rheumatic #diseases flare if #extreme #weather? Even 90 days after extreme weather events flares occur - loss of power, heat’ med storage = ++stressful events Is it early flare from weather & then ++stress @RheumNow @ACRrheum #ACR25 abst#0164 https://t.co/pGPwOKrKU7

Why do pts with #Still’s #AOSD Get hospitalized? #Sepsis 1827 unweighted & 9135 Weighted #US #hospitalizations Worse in men Black Medicaid But is it truly #infection or Still’s flare or both? Abst#0163 ACR25 @RheumNow @rheumacr #ACRBest as largest N ever! https://t.co/fLMNyQQNNj

#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i

In case there was any doubt: GCA leads to ischemic vision loss PMR does not #ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl

Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential. We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF? #ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg

Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA ☝️Consider other dx if D2T PsA #ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ

Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m

After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is. Interesting data but what could explain it? Further studies are needed #ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv

#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R